- |||||||||| Trial completion date, Trial suspension, Trial primary completion date: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=90, Suspended, Active, not recruiting --> Completed Trial completion date: Jun 2019 --> Dec 2019 | Recruiting --> Suspended | Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Potential Research Study Participant Registry (clinicaltrials.gov) - Feb 16, 2019
P=N/A, N=265, Completed, Trial completion date: Jun 2019 --> Dec 2019 | Recruiting --> Suspended | Trial primary completion date: Dec 2018 --> Dec 2019 Recruiting --> Completed | N=200 --> 265 | Trial completion date: Jan 2025 --> Sep 2018 | Trial primary completion date: Jan 2025 --> Sep 2018
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Reducing Skin Cancer Risk in Childhood Cancer Survivors (clinicaltrials.gov) - Jun 20, 2018
P=N/A, N=726, Completed, N=15 --> 29 Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Jan 2018 | Trial primary completion date: Apr 2018 --> Jan 2018
- |||||||||| Trial completion date, Trial primary completion date: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=90, Recruiting, Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Jan 2018 | Trial primary completion date: Apr 2018 --> Jan 2018 Trial completion date: Dec 2017 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| vatalanib (PTK787) / Novartis, Bayer
Trial completion, Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2018 P1, N=96, Completed, Phase classification: P1 --> P=N/A Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
- |||||||||| Samcyprone (diphenylcyclopropenone) / Phio Pharma
Trial completion, Enrollment change, IO biomarker, Immunomodulating: Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (clinicaltrials.gov) - Nov 29, 2017 P1, N=6, Completed, Trial primary completion date: Dec 2016 --> Apr 2015 Active, not recruiting --> Completed | N=13 --> 6
- |||||||||| Samcyprone (diphenylcyclopropenone) / Phio Pharma
Trial primary completion date, IO biomarker, Immunomodulating: Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (clinicaltrials.gov) - Sep 11, 2017 P1, N=13, Active, not recruiting, Enrolling by invitation --> Active, not recruiting Trial primary completion date: Oct 2017 --> Jun 2015
- |||||||||| Trial initiation date, Trial primary completion date, Metastases: Drosophila-generated CTL (clinicaltrials.gov) - Aug 1, 2017
P2, N=3, Terminated, Trial primary completion date: Oct 2017 --> Jun 2015 Initiation date: Dec 2010 --> Apr 2011 | Trial primary completion date: Apr 2012 --> Dec 2011
- |||||||||| Enrollment change, Trial withdrawal, Trial primary completion date, Surgery: Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery (clinicaltrials.gov) - Jul 6, 2017
P=N/A, N=0, Withdrawn, Trial primary completion date: Dec 2017 --> Jul 2016 N=230 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2015 --> Jun 2017
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=23, Completed, N=230 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2015 --> Jun 2017 Active, not recruiting --> Completed | N=55 --> 23 | Trial primary completion date: Jan 2019 --> Jun 2017
- |||||||||| vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 22, 2017 P1, N=96, Active, not recruiting, Active, not recruiting --> Terminated; Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued. Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Trial initiation date, Trial primary completion date: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) - Feb 17, 2017
P=N/A, N=90, Recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2016 Initiation date: Nov 2013 --> Feb 2017 | Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion, Phase classification, Enrollment change, Trial primary completion date, Combination therapy: MEL53: Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma (clinicaltrials.gov) - Dec 16, 2016 P1, N=4, Completed, Completed --> Terminated; Of the 8 histologically proven tumors, detection of PpIX proved to be ambiguous. Suspended --> Completed | Phase classification: PN/A --> P1 | N=24 --> 4 | Trial primary completion date: Jan 2015 --> Jun 2012
- |||||||||| Trial completion, Trial primary completion date: PennSCAPE: Melanoma Risk Assessment & Tailored Intervention (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=323, Completed, Trial primary completion date: Jun 2016 --> Mar 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2011 --> Feb 2016
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: Sunbit UV Measuring Device to Track Sun Behavior (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=10, Terminated, Active, not recruiting --> Completed | Phase classification: P1 --> P1/2 N=20 --> 10 | Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Mar 2016; Company dissolved, no study devices available anymore
- |||||||||| Odomzo (sonidegib) / Sun Pharma, buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Enrollment change, Metastases: Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma (clinicaltrials.gov) - Jun 15, 2016 P=N/A, N=11, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2011 Recruiting --> Active, not recruiting | N=40 --> 11
|